Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
2.

Advances in antifungal chemotherapy.

Fromtling RA.

Drug News Perspect. 1998 Nov;11(9):582-95.

PMID:
15616671
3.

Medical mycology and current trends in antifungal chemotherapy.

Fromtling RA.

Drug News Perspect. 1998 Jun;11(5):310-9.

PMID:
15616652
4.

Human mycoses and current antifungal therapy.

Fromtling RA.

Drug News Perspect. 1998 Apr;11(3):185-91.

PMID:
15616619
5.

Progress in antibacterial and antifungal chemotherapy.

Fromtling RA; European Society of Clinical Microbiology and Infectious Diseases.

Drug News Perspect. 2000 Aug;13(6):366-77.

PMID:
12937659
6.

Human mycoses and advances in antifungal therapy.

Fromtling RA.

Drug News Perspect. 2001 Apr;14(3):181-92.

PMID:
12819825
7.

Micafungin sodium (FK-463).

Fromtling RA.

Drugs Today (Barc). 2002 Apr;38(4):245-57. Review.

PMID:
12532193
8.

Yeasts and fluconazole susceptibility in the Philippines.

Bulmer GS, Marquez ML, Co-Barcelona L, Fromtling RA.

Mycopathologia. 1999;146(3):117-20.

PMID:
10823182
9.

Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Fromtling RA, Galgiani JN, Pfaller MA, Espinel-Ingroff A, Bartizal KF, Bartlett MS, Body BA, Frey C, Hall G, Roberts GD, et al.

Antimicrob Agents Chemother. 1993 Jan;37(1):39-45.

10.

Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Espinel-Ingroff A, Kish CW Jr, Kerkering TM, Fromtling RA, Bartizal K, Galgiani JN, Villareal K, Pfaller MA, Gerarden T, Rinaldi MG, et al.

J Clin Microbiol. 1992 Dec;30(12):3138-45.

11.

Sphingofungins A, B, C, and D; a new family of antifungal agents. I. Fermentation, isolation, and biological activity.

VanMiddlesworth F, Giacobbe RA, Lopez M, Garrity G, Bland JA, Bartizal K, Fromtling RA, Polishook J, Zweerink M, Edison AM, et al.

J Antibiot (Tokyo). 1992 Jun;45(6):861-7.

12.

Restricticin, a novel glycine-containing antifungal agent.

Schwartz RE, Dufresne C, Flor JE, Kempf AJ, Wilson KE, Lam T, Onishi J, Milligan J, Fromtling RA, Abruzzo GK, et al.

J Antibiot (Tokyo). 1991 May;44(5):463-71.

13.

(Acyloxy)alkyl carbamate prodrugs of norfloxacin.

Alexander J, Fromtling RA, Bland JA, Pelak BA, Gilfillan EC.

J Med Chem. 1991 Jan;34(1):78-81.

PMID:
1992156
14.

Collaborative investigation of variables in susceptibility testing of yeasts.

Pfaller MA, Rinaldi MG, Galgiani JN, Bartlett MS, Body BA, Espinel-Ingroff A, Fromtling RA, Hall GS, Hughes CE, Odds FC, et al.

Antimicrob Agents Chemother. 1990 Sep;34(9):1648-54.

15.

Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson KE, Turner MJ.

Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950-4.

16.

Increasing usage of systemic antifungal agents.

Walsh TJ, Jarosinski PF, Fromtling RA.

Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):37-40. No abstract available.

PMID:
2331848
17.

Lack of cross-resistance between efrotomycin and antibacterial agents used in the therapy of human and animal infections.

Jacks TM, Frazier EG, Abruzzo GK, Graham AC, Fromtling RA.

Methods Find Exp Clin Pharmacol. 1989 Nov;11(11):697-701.

PMID:
2695724
18.

L-681,572--a new antifungal agent. Isolation, characterization, and biological activity.

Chaiet L, Fromtling RA, Garrity GM, Monaghan RL, Hensens OD, Valiant ME, Zink DL.

J Antibiot (Tokyo). 1989 Nov;42(11):1718-21. No abstract available.

19.

Isolation of saprophytic Cryptococcus neoformans from Puerto Rico: distribution and variety.

Ruiz A, Vélez D, Fromtling RA.

Mycopathologia. 1989 Jun;106(3):167-70.

PMID:
2682250
20.
21.

L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.

Gilfillan EC, Pelak BA, Weissberger BA, Abruzzo GK, Fromtling RA, Bland JA, Hadley SK, Gadebusch HH.

J Antibiot (Tokyo). 1989 May;42(5):815-22.

22.

L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.

Weissberger BA, Abruzzo GK, Fromtling RA, Gill C, Ponticas S, Valiant ME, Shungu DL, Gadebusch HH.

J Antibiot (Tokyo). 1989 May;42(5):795-806.

23.
24.

L-657,398, a novel antifungal agent: fermentation, isolation, structural elucidation and biological properties.

Schwartz RE, Liesch J, Hensens O, Zitano L, Honeycutt S, Garrity G, Fromtling RA, Onishi J, Monaghan R.

J Antibiot (Tokyo). 1988 Dec;41(12):1774-9.

25.

L-656,575 (OCP-9-176): a novel oxacephem. In vitro activity against aerobic and anaerobic clinical bacterial isolates.

Weissberger B, Abruzzo GK, Fromtling RA, Valiant ME, Shungu DL, Gadebusch HH.

J Antibiot (Tokyo). 1988 Aug;41(8):1130-6.

26.

L-656,575 (OCP-9-176): a novel oxacephem. Pharmacokinetics and experimental chemotherapy.

Gilfillan EC, Pelak BA, Fromtling RA, Bland J, Hadley S, Gadebusch HH.

J Antibiot (Tokyo). 1988 Aug;41(8):1137-41.

27.

Renal pathology and spleen cell chemiluminescence of mice infected with a wild-type and a low-virulence mutant of Candida albicans.

Fromtling RA, Abruzzo GK, Edison A, Manning-Zweerink M.

Zentralbl Bakteriol Mikrobiol Hyg A. 1988 May;268(3):405-15.

PMID:
3043983
28.
29.

Overview of medically important antifungal azole derivatives.

Fromtling RA.

Clin Microbiol Rev. 1988 Apr;1(2):187-217. Review.

30.

Use of chemiluminescence to evaluate the influence of antifungal agents on immune cell function.

Fromtling RA, Abruzzo GK, Turnbull TA, Giltinan DM, Capizzi TP.

Ann N Y Acad Sci. 1988;544:270-83. No abstract available.

PMID:
3214070
31.

Candida tropicalis infection in normal, diabetic, and neutropenic mice.

Fromtling RA, Abruzzo GK, Giltinan DM.

J Clin Microbiol. 1987 Aug;25(8):1416-20.

32.

Lysosomotropic agents. 7. Broad-spectrum antifungal activity of lysosomotropic detergents.

Firestone RA, Pisano JM, Garrity GM, Fromtling RA, Zimmerman SB.

J Med Chem. 1987 Aug;30(8):1519-21.

PMID:
3302260
33.

Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells.

Abruzzo GK, Fromtling RA, Turnbull TA, Giltinan DM.

J Antimicrob Chemother. 1987 Jul;20(1):61-8.

PMID:
3040658
34.

Evaluation of lymphocytes' influence in luminol-dependent chemiluminescence emission of mouse spleen cells.

Müller S, Fromtling RA, Fromtling AM, Pawlak R, Falkenberg S, Gillert KE.

Methods Find Exp Clin Pharmacol. 1986 May;8(5):253-63. Erratum in: Methods Find Exp Clin Pharmacol 1986 Sep;8(9):following 579.

PMID:
2941628
35.

Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells.

Abruzzo GK, Giltinan DM, Capizzi TP, Fromtling RA.

Antimicrob Agents Chemother. 1986 Apr;29(4):602-7.

36.

Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.

Fromtling RA, Abruzzo GK, Bulmer GS.

Mycopathologia. 1986 Apr;94(1):27-30.

PMID:
3014339
37.

Design and analysis considerations in evaluating the chemiluminescence response of mouse spleen cells.

Giltinan DM, Capizzi TP, Abruzzo GK, Fromtling RA.

J Clin Microbiol. 1986 Mar;23(3):531-5.

38.

An overview of macrophage-fungal interactions.

Fromtling RA, Shadomy HJ.

Mycopathologia. 1986 Feb;93(2):77-93. Review.

PMID:
3520327
39.
40.

Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice.

Fromtling RA, Abruzzo GK, Gilfillan EC, Pelak BA, Gadebusch HH.

J Antimicrob Chemother. 1985 Dec;16(6):735-41.

PMID:
3912365
41.

Chemiluminescence as a tool for the evaluation of antimicrobial agents: a review.

Fromtling RA, Abruzzo GK.

Methods Find Exp Clin Pharmacol. 1985 Sep;7(9):493-500. Review.

PMID:
3908855
42.

In vitro effect of pH and glucose concentration on the antibacterial activity of norfloxacin in urine.

Fromtling RA, Abruzzo GK, Gadebusch HH.

Methods Find Exp Clin Pharmacol. 1984 Dec;6(12):737-41.

PMID:
6241649
43.
44.
45.

Cryptococcus neoformans: in vivo protection of mice by pretreatment with pyran copolymer.

Fromtling RA, Shadomy HJ, Kaplan AM.

Mycopathologia. 1984 Mar 15;85(1-2):3-7.

PMID:
6374462
46.

Immunotoxic effects of diethylstilbestrol on host resistance: comparison with cyclophosphamide.

Morahan PS, Bradley SG, Munson AE, Duke S, Fromtling RA, Marciano-Cabral F.

J Leukoc Biol. 1984 Mar;35(3):329-41.

PMID:
6323603
47.

Immunotoxic effects of diethylstilbestrol (DES) and cadmium chloride (CAD) on host resistance: comparison with cyclophosphamide (CPS).

Morahan PS, Bradley SG, Munson AE, Duke S, Fromtling RA, Marciano-Cabral F, Jessee E.

Prog Clin Biol Res. 1984;161:403-6. No abstract available.

PMID:
6483898
49.

Comparative pathogenicity of auxotrophic mutants of Candida albicans.

Manning M, Snoddy CB, Fromtling RA.

Can J Microbiol. 1984 Jan;30(1):31-5.

PMID:
6370397
50.

Ethanol-cephalosporin antibiotic interactions: an animal model for the detection of disulfiram (Antabuse)-like effects.

Fromtling RA, Gadebusch HH.

Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):595-600.

PMID:
6668968

Supplemental Content

Loading ...
Support Center